22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
00:35 , Nov 30, 2016 |  BC Extra  |  Company News

Arrowhead prunes pipeline over toxicity concerns

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) sank $2.63 (60%) to $1.76 in early after-hours trading after it said will discontinue development of all programs using its EX1 liver-targeted, IV delivery vehicle for its RNA therapies. The cuts...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Arrowhead, Amgen deal

Arrowhead granted Amgen exclusive, worldwide rights to the ARC-LPA cardiovascular program and an exclusive option to license a second RNAi therapy against an undisclosed cardiovascular target. Arrowhead will receive $56.5 million up front, including $35...
07:00 , Sep 29, 2016 |  BC Extra  |  Company News

Amgen, Arrowhead in pair of CV deals

In two deals with Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), Amgen Inc. (NASDAQ:AMGN) obtained exclusive, worldwide rights to cardiovascular program ARC-LPA and gained an exclusive option to license a second RNAi therapy against an undisclosed cardiovascular target...